(Q33404760)

English

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Michael S Gordon

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert Ilaria

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dinesh P de Alwis

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David S Mendelson

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Scott McKane

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Margaret M Wagner

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Katherine Y Look

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Patricia M LoRusso

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

11 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

71

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

21-27

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s00280-012-1917-8

0 references

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1917-8

21 January 2018

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1917-8

21 January 2018

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1917-8

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1917-8

21 January 2018

Confidence interval criteria for assessment of dose proportionality.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1917-8

21 January 2018

The turnover rate of serum albumin in man as measured by I131-tagged albumin

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1917-8

21 January 2018

Quantification of lean bodyweight.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1917-8

21 January 2018

A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1917-8

21 January 2018

Identifiers

10.1007/S00280-012-1917-8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33404760&oldid=1980225798"